Psychopharmacological treatment in borderline personality disorder

Actas Espanolas de Psiquiatria

Volumn 36, Issue 1, 2008, Pages 39-49

  Díaz Marsá, Marina ^a   Gonzalez Bardanca S ^b   Tajima, K ^a   Garcia Albea J ^a   Navas, M ^a   Carrasco, J L ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b Servicio de Psiquiatria   (Spain)

Author keywords

Affective instability; Aggressivity; Anxiety; Borderline personality disorder; Cognitive perceptive disfunction; Impulsivity; Treatment

Indexed keywords

4 AMINOBUTYRIC ACID; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CORTICOTROPIN RELEASING FACTOR; FLUOXETINE; LITHIUM CARBONATE; NEUROLEPTIC AGENT; OLANZAPINE; OMEGA 3 FATTY ACID; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

AGGRESSION; AMYGDALOID NUCLEUS; BORDERLINE STATE; HIPPOCAMPUS; HUMAN; IMPULSE CONTROL DISORDER; METABOLISM; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; REVIEW; SEPTUM PELLUCIDUM;

AGGRESSION; AMYGDALA; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BORDERLINE PERSONALITY DISORDER; CORTICOTROPIN-RELEASING HORMONE; FATTY ACIDS, OMEGA-3; FLUOXETINE; GAMMA-AMINOBUTYRIC ACID; HIPPOCAMPUS; HUMANS; IMPULSE CONTROL DISORDERS; LITHIUM CARBONATE; SEPTUM PELLUCIDUM; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; SERTRALINE;

EID: 39849110293     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. Pérez Urdaniz A, Rubio Larrosa V. Tratamiento psicofarmacológico de los trastornos de la personalidad. En: Trastornos de la personalidad. Masson, 2005; p. 345-58.
2. Binks C, Fenton M, McCarthy L. Pharmacological interventions for people with borderline personality disorder. Cochrane Database Syst Rev 2006;25:CD005653.
3. Stone M. The course of BPD. En: Tasman A, et al., editores. American Psychiatric Press Review of Psychiatry, vol 8. Washington: American Psychiatric Press, 1989; p. 103-22.
4. Paris J. Chronic suicidality among patients with BPD. Psychiatr Serv 2002;53:738-42.
5. Akiskal HS, Akiskal K. Cylothymic, hyperthymic and depressive temperaments as subaffective variants of mood disorders. En: Tasman A, Riba MB, editores. Rev Psychiatry 1992; p. 43-62.
6. Bernardo Arroyo M, Roca Bennasar, Benabarre Hernández. Tratamientos biológicos. Masson, 8; p. 153-70.
7. Coccaro EF, Siever LJ. The neuropharmacology of personality disorders. En: Bloom FE, Kupfer DJ, editores. Psychopharmacology: the fourth generation of progress. New York: Raven Press, 1995; p. 1567-79.
8. Akiskal HS. Subaffective disorders: dysthymic, cyclothymic, and bipolar II disorders in the «borderline» realm. Psychiatr Clin North Am 1981;4:25-46.
9. APA Guidelines for treatment BPD. Am J Psychiatry 2001;(Suppl.):158.
10. McGlashan TH. The borderline personality disorder practice guidelines: the good, the bad and the realistic. J Pers Disord 2002;16:119-21.
11. Sanderson C, Swenson CH, Bohus M. A critique of the APA guideline for the treatment of patients with BPD. J Pers Disord 2002;16:122-9.
12. Tyrer P. Practice guideline for the treatment of BPD: a bridge too far. J Pers Disord 2002;16:113-8.
13. Siever LJ, Davis KL. A psychobiological perspective on the personality disorders. Am J Psychiatry 1991;148:1647-58.
14. Stein DJ. Neurobiology of impulsivity and the impulse control disorders. J Neuropsychiatry 1997;58:522-7.
15. Hollander E, de Caria C, Stein D. Behavioral response to m-CPP. Biol Psychiatry 1994;35:426-7.
16. Hollander E, Stein D, de Caria C. Serotoninergic sensitivity in BPD: preliminary findings. Am J Psychiatry 1994;151:277-80.
17. Fava M. Psychopharmacologic treatment of pathologic aggression. Anger, aggression, and violence. Psychiatr Clin N Am, vol 20, 1997.
18. Salzman C, Wolfons AN, Schatzberg A. Effect of fluoxetine on anger in symptomatic volunteers with BPD. J Clin Psychopharmacol 1995;15:23-9.
19. Norden MJ. Fluoxetine in BPD. Prog Neuropsychopharmacol Biol Psychiatr 1989;13:885-93.
20. Coccaro EF, Harvey PH. Development of neuropharmacologically based assessments of impulsive aggressive behavior. J Neuropsychiatry 1991;3(Suppl.):44-51.
21. Markowitz P. Pharmacotherapy of impulsivity, aggression and related disorders. En: Hollander E, Stein D, editores. Impulsivity and aggression. West Susses: John Wiley and Sons, 1995; p. 263-87.
22. Silva H, Jerez S, Paredes A. Fluoxetine in the treatment of borderline personality disorder. Actas Luso Esp Neurol Psiquiatr Cienc Afines 25:391-5.
23. Zanarini MC, Frankenburg FR, Parachini EA. A preliminary, randomized trial of fluoxetine, olanzapine and the olanzapine-fluoxetine combination in women with BPD. J Clin Psychiatry 2004;65:903-7.
24. Zanarini MC. Update on pharmacotherapy of BPD. Curr Psychiatry Rep 2004;6:66-70.
25. Kavoussi RJ, Liu J, Coccaro EF. An open trial of sertraline in personality disorder patients with impulsive aggression. J Clin Psychiatry 1994;55:137-41.
26. Bagby RM, Levitan RD, Kennedy SH. Selective alteration of personality in response to noradrenergic and serotonergic antidepressant medication in depressed sample: evidence of non-specificity. Psychiatry Res 1999;86:211-6.
27. Verkes RJ, van der Mast RC. Reduction by paroxetine of suicidal behavior in patients with repeated suicide attempts but not major depression. Am J Psychiatry 1998;155:543-7.
28. Markovitz PJ, Wagner SC. Venlafaxine in the treatment of BPD. Psychopharmacol Bull 1995;31:773-7.
29. Soloff PH, George A, Nathan S, Schulz PM. Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response. J Clin Psychopharmacol 1989;9:238-46.
30. Parsons, B, Quitkin FM. Phenelzine, imipramine, and placebo in borderline patients meeting criteria for atypical depression. Psychopharmacol Bull 1989;25:524-34.
31. Cowdry R, Gardner D. Pharmacotherapy of BPD: alprazolam, carbamazepine, trifluoperazine and tranylcypromine. Arch Gen Psychiatry 1988;45:111-9.
32. Soloff PH, Cornelius JR, George A. Efficacy of phenelzine and haloperidol in BPD. Arch Gen Psych 1993;50:377-85.
33. Newton-Howes G, Tyrer P. Pharmacotherapy for personality disorders. Expert Opin Pharmacother 2003;4:1643-9.
34. Dawson AH, Whyte IM. Therapeutic drug monitoring in drug overdose. Br J Clin Pharmacol 1999;48:278-83.
35. Schiff. Lithium in aggressive behavior. Am J Psychiatry 1982;139:1346-8.
36. Wilcox JA. Divalproex sodium as a treatment for BPD. Ann Clin Psychiatry 1995;7:33-7.
37. Stein DJ, Simeon D, Frenkel M. An open trial of valproate in BPD. J Clin Psychiatry 1995;56:506-10.
38. Kavoussi RJ, Coccaro EF. Divalproex sodium for impulsive aggressive behaviour in patients with personality disorder. J Clin Psychiatry 1998:59:676-80.
39. Hollander E, Swann AC, Coccaro EF. Impact of trait impulsivity and state aggression on divalproex versus placebo response in BPD. Am J Psychiatry 2005;162:621-4.
40. Frankenburg FR, Zanarini MC. Divalproex sodium treatment of women with BPD and bipolar II disorder: a double-blind placebo-controlled pilot study. J Clin Psychiatry 2002;63:442-6.
41. Pinto OC, Akiskal HS. Lamotrigine as a promising approach to borderline personality: an open case series without concurrent DSM-IV major mood disorder. J Affect Disord 1998;51:333-43.
42. Daly KA, Fatemi SH. Lamotrigine and impulse behaviour. Canad J Psychiatry 1999;44:395-6.
43. Tritt K, Nickel C, Lahmann C. Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. J Psychopharmacol 2005; 19:287-91.
44. Ketter T, Manji H. Potential mechanisms of action of lamotrigine in the treatment of BP. J Clin Psychopharmacol 2003;23:484-5.
45. Bellino S, Paradiso E, Bogetto F. Oxcarbazepine in the treatment of BPD: a pilot study. J Clin Psychiatry 2005;66:1111-5.
46. Cassano P, Lattanzi L, Pini S. Topiramate for self-mutilation in a patient with borderline personality disorder. Bipolar Disord 2001;3:161.
47. Nickel M. Treatment of aggression with topiramate in male borderline patients. A double-blind, placebo-controlled study. Biolog Psychiatry 2005;57:495-9.
48. Nickel M, Nickel C. Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study. J Clin Psychiatry 2004;65:1515-9.
49. Loew T, Nickel M. Topiramate treatment for women with BPD: a double-blind, placebo-controlled study. J Clin Psychopharmacol 2006;26:61-6.
50. Teicher M, Glod C, Aaronson S. Open assessment of the safety and efficacy of thioridazine in the treatment of patients with borderline personality disorder. Psychopharmacol Bull 1989;25:535-49.
51. Kutcher S, Papatheodorou G, Reiter S, Gardner D. The successful pharmacological treatment of adolescents and young adults with borderline personality disorder: a preliminary open trial of flupenthixol. J Psychiatry Neurosci 1995;20:113-8.
52. Benedetti F, Sforzini L, Colombo C. Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder. J Clin Psychiatry 1998;59:103-7.
53. Frankenburg FR, Zanarini MC. Clozapine treatment of borderline patients: a preliminary study. Compr Psychiatry 1993;34:402-05.
54. Chengappa KNR, Ebeling T, Kang JS. Clozapine reduces severe self-mutilation and aggression in psychotic patients with BPD. J Clin Psychiatry 1999;60:477-84.
55. Bogenschutz MP, Nurnberg GH. Olanzapine versus placebo in the treatment of BPD. J Clin Psychiatry 2004;65:104-9.
56. Soler J, Pascual JC, Campins J. Double-Blind, Placebo-Controlled Study of Dialectical Behavior Therapy plus Olanzapine for BPD. Am J Psychiatry 2005;162:1221-4.
57. Hallmayer JF. Olanzapine and women with borderline personality disorder. Curr Psychiatry Rep 2003;5:175.
58. Rocca P, Marchiaro L, Cocuzza E. Treatment of BPD with risperidone. J Clin Psychiatry 2002;63:241-4.
59. Khouzam HR, Donnelly NJ. Remission of self-mutilation in a patient with borderline personality during risperidone therapy. J Nerv Ment Dis 1997;185:348-9.
60. Pascual JC, Madre M, Soler J, Barrachina J, Campins MJ, Álvarez E. Injectable atypical antipsychotics for agitation in borderline personality disorder. Pharmacopsychiatry 2006;39:117-8.
61. Hilger E, Barnas C, Kasper S. Quetiapine in the treatment of borderline personality disorder. World J Biol Psychiatry 2003;4:42-4.
62. Nickel MK, Loew TH, Gil FP. Aripiprazole in treatment of borderline patients, part II: an 18-month follow-up. Psychopharmacology (Berl) 2007;191:1023-6.
63. Peet M, Stokes C. Omega-3 fatty acids in the treatment of psychiatric disorders. Drugs 2005;65:1051-9.
64. Zanarini M, Frankenburg F. Omega 3 fatty acid treatment of women with BPD: a double-blind placebo-controlled pilot study. Am J Psychiaatry 2003;160:167-9.
65. Hamazaki T, Sawazaki S, Itomura M. The effect of docosahexaenoic acid on aggression in young adults: a placebo-controlled double-blind study. J Clin Invest 1996;97:1129-33.
66. Cornelius JR, Soloff PH, Perel JM, Ulrich RF. Fluoxetine trial in borderline personality disorder. Psychopharmacol Bull 1990;26:151-4.
67. Rinne T, de Kloet ER. Fluvoxamine reduces responsiveness of HPA axis in adult female BPD patients with a history of sustained childhood abuse. Neuropsychopharmacology 2003;28:126-32.
68. Ekselius L, Von Knorring L. Personality disorder comorbidity with major depression and response to treatment with sertraline or Citalopram. Int Clin Psychopharmacol 1998;13:205-11.
69. Liebowitz MR, Hollander E. Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders. Acta Psychiatr Scand 1990;360(Suppl.):29-34.
70. Rinne T, van den Brink W. SSRI treatment of BPD: a randomized, placebo-controlled clinical trial for female patients with BPD. Am J Psychiatry 2002;159:2048-54.
71. Hollander E, Allen A, López RP. A preliminary double-blind, placebo-controlled trial of divalproex sodium in BPD. J Clin Psychiatry 2001;62:199-203.
72. th Annual Meeting. Atlanta, 2005.
73. Friedel RO. Dopamine dysfunction in borderline personality disorder: a hypothesis. Neuropsychopharmacology 2004;29:1029-39.
74. Zullino DF, Haefliger QP, Stigler M. Olanzapine improves social dysfunction in cluster B personality disorder. Hum Psychopharmacol 2002;17:247-51.
75. Villenueve E, Lemelin S. Open-label study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: impulsivity as main target. J Clin Psychiatry 2005;66:1298-303.
76. Faltus FJ. The positive effect of alprazolam in the treatment of three patients with borderline personality disorder. Am J Psychiatry 1984;141:802-3.
77. Freinhar JP, Álvarez WA. Clonazepam: a novel therapeutic adjunct. Int J Psychiatry Med 1985;15:321-8.